Latest news with #Endologix
Globe and Mail
19-05-2025
- Business
- Globe and Mail
Abdominal Aortic Stent Grafts Market to Witness Upsurge in Growth by 2030, Assesses DelveInsight
DelveInsight's Abdominal Aortic Stent Market Insights Report provides the current and forecast market analysis, individual leading Abdominal Aortic Stent Companies market shares, challenges, Abdominal Aortic Stent Market Drivers, barriers, trends, and key market Abdominal Aortic Stent Companies in the market. To read more about the latest highlights related to the Abdominal Aortic Stent Market, get a snapshot of the key highlights entailed in the Market Report @ Abdominal Aortic Stent Grafts Pipeline Product Market Key Takeaways from the Abdominal Aortic Stent Market Report The Global Abdominal Aortic Stent Grafts Market is estimated to grow at a CAGR of 4.31% during the forecast period from 2024 to 2030. The Abdominal Aortic Stent Grafts Market is experiencing significant growth, driven by the increasing prevalence of abdominal aortic aneurysms (AAA) and the rising demand for minimally invasive surgical procedures. The leading Abdominal Stent Graft Companies such as Endologix LLC., Medtronic, Terumo Aortic, MicroPort Scientific Corporation, Cook Medical, Cordis, JOTEC GmbH, W. L. Gore & Associates, Inc., Lombard Medical, Lifetech Scientific, SB-Kawasumi Laboratories, Inc., Endospan, Cardinal Health, Artivion Inc., Latecba SA, Nectero Medical, Cardiatis SA, Hangzhou Endonom Medtech Co., Ltd., and others. To know more about why North America is leading the market growth in the Abdominal Aortic Stent Grafts Market, get a snapshot @ Abdominal Aortic Stent Grafts Market Outlook Abdominal Aortic Stent Grafts Market Dynamics According to the estimates of DelveInsight the total diagnosed prevalent population of abdominal aortic aneurysm (AAA) in 7MM was estimated to be 1,641,380 cases in 2021. This anticipated surge in AAA cases is likely to drive the demand for abdominal stent-grafts, as they are essential medical devices used for treating abdominal aortic aneurysms thereby boosting the future market of the abdominal stent graft. Abdominal Stent Graft Market Segment Analysis Abdominal Stent Graft Market by Material Type (Metal and Polymer), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). In the product segment of the abdominal stent graft market, the metal abdominal stent graft is estimated to have a significant revenue share in the abdominal stent graft market in 2023. This can be attributed to the various advantages and applications provided by the metal abdominal stent graft. Metal abdominal stent grafts offer advantages over polymer ones due to their greater durability, flexibility, and radial force. Metal stents provide better support for the vessel wall, reducing the risk of migration and endoleaks. Additionally, metal stents can be more easily repositioned during deployment and offer improved visibility under imaging, facilitating precise placement. Get a sneak peek at the Abdominal Aortic Stent Grafts Market Dynamics @ Abdominal Aortic Stent Grafts Product Market Outlook Abdominal Aortic Stent Grafts Companies Endologix LLC., Medtronic, Terumo Aortic, MicroPort Scientific Corporation, Cook Medical, Cordis, JOTEC GmbH, W. L. Gore & Associates, Inc., Lombard Medical, Lifetech Scientific, SB-Kawasumi Laboratories, Inc., Endospan, Cardinal Health, Artivion Inc., Latecba SA, Nectero Medical, Cardiatis SA, Hangzhou Endonom Medtech Co., Ltd., and others. Global Abdominal Stent Graft Market Drivers The demand for abdominal stent grafts is primarily being boosted by the growing prevalence of abdominal aortic aneurysms and other related issues such as atherosclerosis. Furthermore, the market for abdominal stent grafts is boosted by the rising prevalence of cardiac disease due to smoking, obesity, and high blood pressure as these complications are significant risk factors for the development and progression of abdominal aortic aneurysms. Additionally, the abdominal stent graft market is anticipated to grow on account of increasing number of product approvals, and product launches. Which MedTech key players in the Abdominal Aortic Stent Grafts Market are set to emerge as the trendsetter explore @ Abdominal Aortic Stent Grafts Companies Scope of the Abdominal Aortic Stent Grafts Market Report Coverage- Global Abdominal Aortic Stent Grafts Companies- Endologix LLC., Medtronic, Terumo Aortic, MicroPort Scientific Corporation, Cook Medical, Cordis, JOTEC GmbH, W. L. Gore & Associates, Inc., Lombard Medical, Lifetech Scientific, SB-Kawasumi Laboratories, Inc., Endospan, Cardinal Health, Artivion Inc., Latecba SA, Nectero Medical, Cardiatis SA, Hangzhou Endonom Medtech Co., Ltd., and others. Abdominal Aortic Stent Grafts Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Interested in knowing the Abdominal Aortic Stent Grafts Market by 2030? Click to get a snapshot of the Abdominal Aortic Stent Grafts Market Trends Table of Contents 1. Abdominal Stent Graft Market Report Introduction 2. Abdominal Stent Graft Market Executive Summary 3. Competitive Landscape 4. Regulatory Analysis 5. Abdominal Stent Graft Market Key Factors Analysis 6. Abdominal Stent Graft Market Porter's Five Forces Analysis 7. Abdominal Stent Graft Market Assessment 8. Abdominal Stent Graft Market Company and Product Profiles 9. KOL Views 10. Project Approach 11. About DelveInsight 12. Disclaimer & Contact Us About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Associated Press
03-03-2025
- Business
- Associated Press
Endologix Appoints Andrew Davis as Chief Commercial Officer
Endologix LLC, a privately held global medical device company specializing in innovative therapies for vascular disease, is pleased to announce the appointment of Andrew Davis as its new Chief Commercial Officer, effective immediately. Andrew joins Endologix with an extensive background in commercial leadership, having most recently served as the Chief Commercial Officer at Silk Road Medical where he successfully spearheaded the go-to-market strategy for a groundbreaking therapy to treat carotid artery disease (TCAR). With expertise in revenue optimization, customer engagement, and market expansion, he is poised to play a key role in advancing the company's strategic objectives. Andy brings to Endologix over 25 years of experience in the medical device field, as well as expertise in launching innovative, minimally invasive therapies that increase patient access and solve unmet clinical needs in cardiovascular diseases. Prior to joining Silk Road Medical, Andy was the Vice President of Sales and Marketing at 3M's Advanced Wound Therapy Group. Prior to 3M, he spent 15 years at Medtronic and held various Vice President of Sales positions in Cardiac and Vascular Therapies to include TAVR, Endovascular EVAR/TEVAR, Peripheral Vascular, and Spine/Biologics. Andy received a B.S. in Political Science from Florida State University. 'We are thrilled to welcome Andrew Davis to our leadership team,' said Dr. John Liddicoat, President and Chief Executive Officer at Endologix. 'He brings a strong track record of success and innovation in the commercial space, and we are confident that his leadership will help us accelerate our growth and strengthen our market position.' In this role, Andrew will focus on aligning commercial operations with the company's long-term vision, enhancing customer relationships, and driving new business opportunities. His leadership will be instrumental in executing Endologix's ambitious growth plans. 'I am excited to join Endologix at such a pivotal moment,' said Andrew Davis. 'I look forward to working with the talented team here to expand our market presence, drive revenue growth, and deliver exceptional value to our customers.' About Endologix Endologix LLC is a California-based, global medical device company dedicated to improving patients' lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix's therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases that currently have clinically relevant unmet needs. Endologix's commercial products, including the AFX®2 Endovascular AAA System, ALTO® Abdominal Stent Graft System, and the DETOUR™ System, are designed to treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. The company has offices and manufacturing sites in Irvine, Milpitas and Santa Rosa, California. To learn more about Endologix, please visit SOURCE: Endologix LLC Copyright Business Wire 2025. PUB: 03/03/2025 05:00 AM/DISC: 03/03/2025 05:00 AM
